

# TABLE OF CONTENTS

## **I. THE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY**

<b>1. HISTORY AND PURPOSE OF THE AGENCY</b>	<b>1</b>
<b>2. SUMMARY OF OPERATIONS</b>	
(1) Adverse Health Effect Relief Services	4
(2) Review and Related Operations	4
(3) Post-marketing Safety Operations	5

## **II. OPERATION RESULTS/ACHIEVEMENT OF FY 2005**

### **PART 1. IMPROVEMENT IN OVERALL OPERATIONS AND QUALITY IN SERVICE OF THE AGENCY**

(1) Development and Implementation of 2005 Fiscal Year Plan	7
(2) Efficient and Flexible Operations	
1. Operation through target management	8
2. Enhancement of operational and top management	9
3. Meeting of advisory councils	11
4. More efficient operation system	12
5. Standardization of operating procedures	13
6. Development of information system	13
(3) Cost Reduction by Increased Efficiency of Operations	
1. Reduction of general management expenses	14
2. Reduction of project expenses	15
3. Collection and management of contributions	18
(4) Improvement of Services to Public	
1. General consultation service	20
2. Responses to complaints and appeals from companies regarding reviews and post-marketing safety operations	21

3. More information on website	21
4. National Forum on Drugs and Medical Devices	21
5. Report on financial standing	22
6. Internal auditing and related matters	22
<b>(5) Personnel Issues</b>	
1. Discussion of a personnel evaluation system	23
2. Systematic implementation of staff training	23
3. Appropriate personnel allocation	25
4. Securing human resources through open recruitment	25
5. Appropriate personnel management based on work regulations	27
<b>(6) Ensuring Security</b>	
1. Office entrance/exit controls	28
2. Security of information system	28

**PART 2. IMPROVEMENT IN OPERATION OF EACH DEPARTMENT OF THE AGENCY, AND IN ITS QUALITY SERVICE**

<b>1. ADVERSE HEALTH EFFECT RELIEF SERVICES</b>	<b>29</b>
(1) Expeditious Processing of Relief Applications	29
(2) Unified Management of Information through Database	31
(3) Promotion of Appropriate Communication of Information through Interdepartmental Collaboration	31
(4) Surveys on Actual Damages from Adverse Drug Reactions (ADRs)	32
(5) Expansion of Consultation Service	32
(6) Expansion and Review of Information Dissemination Regarding Relief Services	
1. Disclosure of judged cases on relief benefit payment on website	33
2. Improvement of pamphlets and other communication tools	33
(7) Proactive Public Relations Activities	33
(8) Appropriate Relief Services for SMON (subacute myelo-optico-neuropathy) Patients and HIV-positive and AIDS Patients Infected by Blood Preparations	35

**2. REVIEWS AND RELATED OPERATIONS/ POST-MARKETING SAFETY OPERATIONS**

<b>(1) Faster Access to Innovative Pharmaceuticals and Medical Devices</b>	
1. Ensuring the benefits of pharmaceuticals and medical devices for the public and healthcare Professionals	

a. Clinical trial consultations and reviews	37
b. Grasping the needs of public and healthcare professionals	45
2. Efforts for efficient and prompt reviews	
a. Approval Review for new pharmaceuticals	46
b. Review of new medical devices	50
c. Compliance review of application materials, GLP, GCP and GPMSP review	53
d. Approval review for generic drugs, over-the-counter (OTC) drugs and quasi-drugs	54
3. Reinforcement of clinical trial consultation system	
a. Establishment of priority consultation system	56
b. Acceleration of clinical trial consultations for drugs	57
4. Promotion of international harmonization	
a. Approach to international harmonization in ICH and others	58
b. Introduction of total review process time (system/idea)	59
 (2) Improvement of Reliability in Operations	
1. Planned recruitment of staff with advanced expertise and systematic provision of training opportunities	60
2. Development of GMP on-site review system	60
3. Effective use of external experts	62
4. System development for efficient review operations	62
5. Strengthening of partnership with foreign regulatory authorities	63
6. Evaluation of such advanced technologies as biotechnology and genomics/ Cooperation in developing national guidelines	64
7. Promotion of appropriate clinical trials	64
8. Prompt provision of information such as review reports	65
 (3) Reinforcement of Post-Marketing Safety Operations including information management and risk management system	
1. Basic direction of post-marketing safety measures	66
2. Introduction of new method (Study to introduce data mining technique)	66
3. Establishment of sentinel medical institution network	72
4. Study on system for collection and evaluation of information/reports on medical device malfunctions	74
5. Proper examination of reports on ADRs and medical device malfunction	75

6. Online reporting system on ADRs and medical device malfunctions	76
7. Establishment of post-marketing safety system through information feedback	
a. Feedback to companies	77
b. Feedback to health professionals	77
c. Telephone consultation service for general consumers and patients	80
d. Improvement of content and its quality of disseminating information	81

### **III. SUPPORTING INFORMATION**

#### **PART 1. OPERATIONS RELATED TO ADVERSE HEALTH EFFECT RELIEF SERVICES**

##### **1. ADVERSE DRUG REACTION RELIEF SERVICE**

(1) Number of Applications for Benefits and Judged Cases	83
(2) Contributions for adverse health effect relief service	85
(3) Liability Reserve	86
(4) Consultation Service	86
(5) Health and Welfare Services	87

##### **2. BIO-DERIVED PRODUCTS CAUSED INFECTIONS RELIEF SERVICE**

(1) Relief Benefits for Infectious Disease Sufferers	88
(2) Contributions for infections disease relief service	88

##### **3. RELIEF SERVICES RELATED TO SMON (Commissioned and lending services)**

##### **4. RELIEF SERVICE RELATED TO AIDS (Commissioned support service)**

#### **PART 2. REVIEW RELATED OPERATIONS AND POST-MARKETING OPERATIONS**

##### **1. FACE-TO-FACE CONSULTATION**

(1) Existing Services	91
(2) New Services from FY 2004	94
1. Simplified consultation services concerning generic drugs, over-the-counter (OTC) drugs and quasi drugs	94
2. CTCs and pre-application consultations services for medical devices and in vitro diagnostics	94

3. Simple consultation services regarding medical devices and in vitro diagnostic drugs	94
4. Preliminary interview for medical devices and in vitro diagnostics	94
5. Priority consultations for designated applications	94
<b>2. APPROVAL REVIEW OPERATIONS FOR DRUGS, ETC.</b>	
(1) Approval Review for Drugs and Quasi Drugs	95
1. Approval review for new drugs	95
2. Review for the approval of prioritized applications	96
3. Disclosure of review progress to applicants	97
(2) Re-examination and Re-evaluation of Approved Drugs	98
<b>3. REVIEW FOR MEDICAL DEVICES AND IN VITRO DIAGNOSTICS APPROVAL</b>	
(1) Approval Review for Medical Devices	98
1. Approval review for new medical devices	100
2. Approval review for improved medical devices	100
3. Number of cases approved by using foreign clinical data	101
4. Approval review for generic medical devices	101
5. Approval review for prioritized medical devices	101
6. Disclosure about review progress to applicants	101
(2) Approval review for in vitro diagnostics	
1. Approval review for in vitro diagnostics	
2. Change of application categories and the number of application under the new categories	102
<b>4. CONFORMITY AUDIT</b>	
(1) Conformity Audit for Application Materials for New Drug Approval	103
(2) Conformity Audit for Generic Drugs	103
(3) Conformity Audit of Application Materials for Re-examination	103
(4) Conformity Audit of Application Materials for Re-evaluation	103
(5) On-site Conformity Review of Pharmaceuticals and Medical Devices Safety Tests (GLP Review)	104
(6) On-site Conformity Review of Drug Clinical Study (GCP Review)	
1. GCP review for new drugs	104
2. GCP review for generic drugs	104
(7) On-site GPMSP*/GPSP review	104

## **5. OTHER SERVICES RELATED TO REVIEWS**

<b>(1) Investigation of Notified CT Protocol</b>	<b>105</b>
<b>(2) Investigation on Reported Adverse Health Effects (AHEs) that Happened in Clinical Trials</b>	<b>106</b>
<b>(3) Services Related to Prior Assessment on Pharmaceuticals / Medical Devices that Utilize Cells and Tissues, Drugs for Gene Therapy and Cartagena Related Issues etc.</b>	<b>106</b>
<b>(4) Registration of Drug Master File (etc.)</b>	<b>107</b>
<b>(5) Review and Confirmation of Exporting License Application</b>	<b>107</b>

## **6. ASSURANCE OF COMPLIANCE AND STANDARD AND QUALITY CONTROL**

<b>(1) On-site GMP Audit of Pharmaceuticals etc.</b>	<b>107</b>
<b>(2) Audit of buildings and facilities</b>	<b>109</b>
<b>(3) On-site inspections etc.</b>	<b>111</b>
<b>(4) Making draft standards</b>	<b>111</b>

## **7. POST-MARKETING SAFETY OPERATIONS**

<b>(1) Collection of ADR Reports</b>	<b>112</b>
<b>(2) Investigation of ADR reports and others</b>	<b>113</b>
<b>(3) Providing Safety Information</b>	<b>114</b>
<b>(4) Consultation Services for Consumers</b>	<b>116</b>
<b>(5) Collection of Safety Measures Contributions</b>	<b>123</b>

**Incorporated Administrative Agency – Pharmaceutical and Medical Devices Agency (PMDA)**

**Midterm Targets** **125**

**Incorporated Administrative Agency – Pharmaceutical and Medical Devices Agency (PMDA)**

**Midterm Plan** **132**

## **IV. STATISTICAL TABLES**

### **1. Adverse Health Effect Relief Services**

<b>Table 1</b>	<b>Number of cases on adverse health effect relief benefits 1980-2005</b>	<b>148</b>
<b>Table 2</b>	<b>Number of claims and benefit amounts in adverse health effect relief services</b>	<b>149</b>
<b>Table 3</b>	<b>Number of claims and benefits for adverse health effect relief services in prefectures</b>	<b>151</b>
<b>Table 4</b>	<b>Yearly trend of diseases (symptoms) caused by adverse reactions</b>	<b>152</b>

<b>Table 5</b>	<b>Yearly trend of the number of pharmaceuticals that caused adverse reactions by drug therapeutic class</b>	<b>153</b>
<b>Table 6</b>	<b>Adverse drug reaction contributions from marketing authorization holders</b>	<b>154</b>
<b>Table 7</b>	<b>Number of consultations for relief benefits</b>	<b>155</b>
<b>Table 8</b>	<b>Relief service for infectious disease caused by bio-derived products</b>	<b>156</b>

#### **Relief Service for SMON Patients**

<b>Table 9</b>	<b>Payment of healthcare allowances and nursing expenses</b>	<b>157</b>
----------------	--	------------

#### **Relief Service for HIV-positive and AIDS Patients**

<b>Table 10</b>	<b>Number of claim cases and benefit amounts related to research and study projects</b>	<b>158</b>
<b>Table 11</b>	<b>Number of claim cases and benefit amounts released to healthcare support service</b>	<b>159</b>
<b>Table 12</b>	<b>Number of claims and benefit amounts by types in relief services for HIV-positive and AIDS patients</b>	<b>160</b>
<b>Table 13</b>	<b>Number of consultation for relief services</b>	<b>161</b>

#### **2. Review Related Operations and Post-marketing Operations**

<b>Table 14</b>	<b>Number of applications and approvals for drugs (FY1998 – FY2005)</b>	<b>162</b>
<b>Table 15</b>	<b>Number of applications and approvals for medical devices (FY1998 – FY2005)</b>	<b>163</b>
<b>Table 16</b>	<b>Review status for generic drugs, etc. in FY 2005</b>	<b>164</b>
<b>Table 17</b>	<b>Clinical trial consultation achievements (FY1999-FY2005)</b>	<b>165</b>
<b>Table 18</b>	<b>A list of approved articles in 2005 (new drugs)</b>	<b>168</b>
<b>Table 19</b>	<b>A list of approved articles in 2005 (new medical devices)</b>	<b>173</b>
<b>Table 20</b>	<b>Number of reports on ADRs and medical device malfunctions</b>	<b>174</b>
<b>Table 21</b>	<b>Measures for safety strategies and revision to "precautions on use" related to pharmaceuticals implemented by the Ministry of Health, Labour and Welfare in 2005</b>	<b>175</b>
<b>Table 22</b>	<b>Revision of the "Precautions on Use" in relation to medical devices in 2005 ordered by MHLW and notification of self-assessment</b>	<b>186</b>
<b>Table 23</b>	<b>Pharmaceuticals and medical devices safety information (No. 212-223) in 2005</b>	<b>187</b>
<b>Table 24</b>	<b>User fee lists</b>	<b>190</b>